AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02414451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules
Study NCT03180593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
Study NCT03173027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fangji Huangqi pill or Fangji Huangqi pill placebo
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Study NCT03173027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fangji Huangqi pill or Fangji Huangqi pill placebo
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Study NCT02929927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: tooth was isolated using a rubber dam in order to avoid the outside microbe
Study NCT02929927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aPDT
Description: Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
Study NCT02929927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% iodine tincture
Description: use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
Study NCT02929927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5%NaClO
Description: use 2.5% NaClO as irrigants
Study NCT02929927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal preparation
Description: mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
Study NCT02929927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal obturation
Description: filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
Study NCT02043158 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
Study NCT02043158 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
Study NCT00037752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
Study NCT00037752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation Program
Description: Both groups of participants will take part in a behavioral smoking cessation program.
Study NCT02330016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voluma XC
Description: Voluma XC
Study NCT04085744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10% Spray
Description: lidocaine will be apply on the cuff
Study NCT04085744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone nasal spray
Description: mometasone spray will be applied on the cuff
Study NCT03282539 — intervention group
Intervention type: DEVICE
Intervention: LAMS
Description: EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
Study NCT03282539 — intervention group
Intervention type: DEVICE
Intervention: LAMS + pigtail
Description: EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
Study NCT03045133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
Study NCT03045133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
Study NCT00830167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Study NCT00830167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Study NCT01462578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
Study NCT01080586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Study NCT01080586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Capsules USP (Modified) 100 mg
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Chemotherapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: endocrine therapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: endocrine therapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: endocrine therapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: endocrine therapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study NCT02014558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
Study NCT02014558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
Study NCT03032159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2Breathe Study Group
Study NCT04139694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food plan with cinnamon supplementation
Description: cinnamon twice daily plus follow Cardiometabolic diet
Study NCT04139694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food plan without cinnamon supplementation
Description: Cardiometabolic diet only
Study NCT01365338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT01365338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study NCT02979483 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrative supportive care
Description: At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~* Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened
Study NCT03057379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Reminder Recall
Description: The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
Study NCT02897765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal cancer vaccine
Study NCT02897765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: monoclonal antibody against PD1
Study NCT03981549 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Bone Marrow CD34+ Stem Cells
Description: Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
Study NCT03981549 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Autologous Bone Marrow CD34+ Stem Cells
Description: Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
Study NCT03981549 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Therapy
Description: Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
Study NCT03981549 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
Study NCT02897765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: chemotherapy
Study NCT04137224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Description: Human normal immunoglobulin for subcutaneous administration
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: chemotherapy
Study NCT04137224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Human normal immunoglobulin for intravenous administration
Study NCT01669928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive Medication -
Description: Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).
Study NCT00690222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection of mydriatic agent
Description: A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
Study NCT01008254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical prompt
Description: Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
Study NCT01008254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed musical prompt
Description: Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
Study NCT01008254 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No musical prompt
Description: No intervention.
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: endocrine therapy
Study NCT02344472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: endocrine therapy
Study NCT01213251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Site Pacing
Description: Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
Study NCT01213251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Site Pacing
Description: Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
Study NCT01121029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
Study NCT06098352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEBL Continuous Performance Task
Description: A PEBL version of the Conners Continuous Performance Task
Study NCT03811119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MANTA vascular closure device
Description: Collagen based vascular closure device
Study NCT03811119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture based vascular closure device
Description: Suture based vascular closure device (ProGlide)
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 4 mg
Description: Fesoterodine 4 mg tablet once daily for 24 weeks
Study NCT03833427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.
Study NCT03833427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
Study NCT01663467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Description: Ginexin-F 80mg tablet will be given twice a day for 6 months.
Study NCT01663467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginexin-F 80mg tablet will be given twice a day for 6 months.
Study NCT01663467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified TRT
Description: modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months.
Study NCT04220229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT04220229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT01557244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
Study NCT02836275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion/Perfusion-weighted Magnetic Resonance Imaging
Study NCT03387683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: dapagliflozin 10mg
Study NCT03387683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match dapagliflozin
Study NCT03583723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy Group
Description: Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
Study NCT00629772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
Study NCT00629772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
Study NCT02778867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Food Elimination Diet Therapy
Study NCT02778867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 Food Elimination Diet Therapy
Study NCT00629772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
Study NCT00729287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study NCT02467582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg daily
Study NCT02467582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05927480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio distraction
Description: Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
Study NCT01682538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitisinone, capsule
Study NCT01682538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone, suspension
Study NCT00729287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally